This finding indicates that there is a significant co-occurrence (p = 0.00004) of MLH1 loss and NDUFA9 mutations in colorectal adenocarcinoma patients, therefore supporting our in vitro data. The gene discussed is MLH1; the disease is colorectal adenocarcinoma.